`

Tagged: PH1

New Drug Approved in the Field of SiRNA-based Therapeutics Targeting Rare Disease

May 5th, 2021 | PH1

Lumasiran, a siRNA Therapeutic drug for primary hyperoxaluria type1(PH1) By: Dr. Maria Niu PH1 is a rare genetic disease caused by deficiency of the liver peroxisomal enzyme alanine:glyoxylate-aminotransferase (AGT), resulting in overproduction of oxalate. The clinical manifestation includes kidney stones, widespread organ damage, and kidney failure. Liver transplantation is applied in PH1 patients to provide the […]

Pin It on Pinterest